BCR-ABL1-IN-2
BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research[1].
Product Specifications
UNSPSC
12352005
Target
Bcr-Abl
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(C1=CC=C(C=C1)CN2CCC(C3=CC=C(C=C3)N)CC2)NC4=CC=C(C(NC5=NC=CC(C6=CC=CN=C6)=N5)=C4)C
Molecular Formula
C35H35N7O
Molecular Weight
569.70
References & Citations
[1]Chowdhury MM, et al. Design, Synthesis, and Biological Evaluation of Efflux-Resistant Imatinib Derivatives. J Med Chem. 2025 Nov 13;68 (21) :22619-22632.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcr-Abl
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY402391 100 µg
DCL 1 (CD302) (NM_014880) Human Over-expression Lysate
Sign In for Pricing
View Details 